TME Pharma N.V. (FR:ALTME)
:ALTME
Want to see FR:ALTME full AI Analyst Report?
ALTME Stock Chart & Stats
€0.06
<€0.01(2.26%)
At close: 4:00 PM EST
€0.06
<€0.01(2.26%)
Day’s Range― - ―
52-Week Range€0.05 - €0.15
Previous CloseN/A
Volume26.06K
Average Volume (3M)547.76K
Market Cap
€7.96M
Enterprise Value€8.61M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.66M
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage Oncology PipelineAs a clinical-stage biotech concentrating on the tumor microenvironment and targeted cancer therapies, the company has a clear strategic focus that aligns with structural demand for novel oncology treatments. This specialization can generate durable value on successful trial readouts and partnerships, concentrating R&D resources on high-impact indications over a multi-quarter horizon.
Lean Operating StructureA very small headcount suggests a lean cost base and reliance on outsourced R&D or partnerships, which can extend operational runway per funding round and enable nimble decision-making. Over months, lower fixed payroll expense supports capital efficiency and makes incremental funding go further for clinical programs.
Narrowing Historical Losses Versus 2021–2022The material narrowing of losses versus 2021–2022 indicates improved expense control or program prioritization. Sustained reduction in operating losses over multiple periods can lower near-term financing needs and demonstrates management’s ability to better align spending with strategic milestones, a positive structural trend if maintained.
Bears Say
Pre-commercial With Near-zero RevenueThe absence of commercial revenue leaves the business dependent on external financing and milestone/partner payments. Over the coming months this structural lack of diversified cash inflows limits self-funding of trials, increases fundraising frequency, and reduces revenue visibility, raising execution risk.
Negative Equity And Sharply Higher 2025 DebtNegative equity and a marked increase in absolute debt weaken solvency metrics and constrain financing flexibility. Over a 2–6 month horizon, this raises refinancing and covenant risk, can limit access to traditional credit, and increases the likelihood of dilutive equity raises or onerous financing terms if cash needs persist.
Persistent Cash Burn And Deteriorating 2025 Free Cash FlowConsistent negative operating and free cash flow, with deterioration in 2025, means the company must repeatedly tap external capital to fund operations. Structurally, ongoing burn increases dilution and can force reprioritization or delays in clinical programs if fundraising windows close or terms worsen.
TME Pharma N.V. News
ALTME FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.15 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €7.96M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Oct 29, 2026 which is in 161 days.
How were TME Pharma N.V.’s earnings last quarter?
Currently, no data Available
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,188,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―